Santiago Uranga
Overview
Explore the profile of Santiago Uranga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvo S, Rodrigo-Munoz J, Tarancon R, Uranga S, Martin C, Del Pozo V, et al.
EBioMedicine
. 2025 Feb;
113:105637.
PMID: 40015173
No abstract available.
2.
Calvo S, Rodrigo-Munoz J, Tarancon R, Uranga S, Martin C, Del Pozo V, et al.
EBioMedicine
. 2024 Aug;
107:105272.
PMID: 39173529
Background: MTBVAC is a live attenuated tuberculosis vaccine, currently undergoing phase III evaluation for tuberculosis prevention. In previous preclinical studies, we found that local pulmonary administration of MTBVAC via the...
3.
Campos-Pardos E, Uranga S, Pico A, Gomez A, Gonzalo-Asensio J
Nat Commun
. 2024 Mar;
15(1):2161.
PMID: 38461302
Human and animal tuberculosis is caused by the Mycobacterium tuberculosis Complex (MTBC), which has evolved a genomic decay of cobalamin (vitamin B12) biosynthetic genes. Accordingly, and in sharp contrast to...
4.
Moreo E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, Guerrero C, Gomez A, et al.
Nat Commun
. 2023 Oct;
14(1):6090.
PMID: 37794033
Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of...
5.
Moreo E, Uranga S, Pico A, Gomez A, Nardelli-Haefliger D, Del Fresno C, et al.
J Immunother Cancer
. 2022 Jul;
10(7).
PMID: 35781395
Background: Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed....
6.
Perez I, Campos-Pardos E, Diaz C, Uranga S, Sayes F, Vicente F, et al.
Mol Ther Nucleic Acids
. 2022 Mar;
27:1235-1248.
PMID: 35282413
Cyclic (di)nucleotides act as universal second messengers endogenously produced by several pathogens. Specifically, the roles of c-di-AMP in immunity and virulence have been largely explored, although its contribution to the...
7.
Mata E, Tarancon R, Guerrero C, Moreo E, Moreau F, Uranga S, et al.
Sci Immunol
. 2021 Sep;
6(63):eabc2934.
PMID: 34559551
Bacillus Calmette-Guerin (BCG) is an attenuated bacterial vaccine used to protect against () in regions where infections are highly prevalent. BCG is currently delivered by the intradermal route, but alternative...
8.
Broset E, Calvet Seral J, Arnal C, Uranga S, Kanno A, Leite L, et al.
Comput Struct Biotechnol J
. 2021 Aug;
19:4273-4283.
PMID: 34429847
Live vaccines are attractive vehicles for antigen delivery as a strategy to immunize against heterologous pathogens. The live vaccine MTBVAC is based on rational attenuation of with the objective of...
9.
Tarancon R, Mata E, Uranga S, Gomez A, Marinova D, Otal I, et al.
EBioMedicine
. 2021 Jan;
64:103186.
PMID: 33478923
Background: Substantial recent advances in the comprehension of the molecular and cellular mechanisms behind asthma have evidenced the importance of the lung immune environment for disease outcome, making modulation of...
10.
Mata E, Farrell D, Ma R, Uranga S, Gomez A, Monzon M, et al.
PLoS Pathog
. 2020 Dec;
16(12):e1009061.
PMID: 33347499
Species belonging to the Mycobacterium tuberculosis Complex (MTBC) show more than 99% genetic identity but exhibit distinct host preference and virulence. The molecular genetic changes that underly host specificity and...